Evidence map›Paper›PMID 36304100›Full record

ArticleiScience2022

Adult

Pomme M F Rigter, Ilse Wallaard, Mehrnoush Aghadavoud Jolfaei, Jenina Kingma, Laura Post, Minetta Elgersma, Ype Elgersma, Geeske M van Woerden

Open access · goldAbstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Role of CAMK2D in neurodevelopment and associated conditions.American journal of human genetics · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Pomme M F RigterDepartment of Clinical Genetics, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands.
Ilse WallaardDepartment of Clinical Genetics, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands.
Mehrnoush Aghadavoud JolfaeiDepartment of Clinical Genetics, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands.
Jenina KingmaDepartment of Clinical Genetics, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands.
Laura PostDepartment of Neuroscience, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands.
Minetta ElgersmaDepartment of Clinical Genetics, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands.
Ype ElgersmaDepartment of Clinical Genetics, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands.
Geeske M van WoerdenDepartment of Clinical Genetics, Erasmus Medical Center, 3015GD Rotterdam, the Netherlands.
Erasmus University Rotterdam · NLErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the recent findings that mutations in the gene encoding the α-subunit of calcium/calmodulin-dependent protein kinase II (CAMK2A) causes a neurodevelopmental disorder (NDD), it is of great therapeutic relevance to know if there exists a critical developmental time window in which CAMK2A needs to be expressed for normal brain development, or whether expression of the protein at later stages is still beneficial to restore normal functioning. To answer this question, we generated an inducible

Indexed as

Cell biologyCellular neuroscienceDevelopmental biology

Identifiers

PMID36304100
PMCPMC9593899
OpenAlexW4303575151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.